Vγ9Vδ2 T Cell-based Immunotherapy in Hematological Malignancies: from Bench to Bedside

Overview

Journal Cell Mol Life Sci

Publisher Springer

Specialty Biology

Date 2011 May 18

PMID 21584812

Citations 22

Authors

Barbara Castella

Candida Vitale

Marta Coscia

Massimo Massaia

Affiliations

Soon will be listed here.

Abstract

Many hematological malignancies consist of tumor cells that are spontaneously recognized and killed by Vγ9Vδ2 T cells. These tumor cells generate high amounts of intracellular phosphorylated metabolites mimicking the natural ligands and display a wide range of stress-induced self-ligands that are recognized by Vγ9Vδ2 T cells via TCR-dependent and TCR-independent mechanisms. The intrinsic features of Vγ9Vδ2 T cells and that of tumor cells of hematological origin constitute an ideal combination from which to develop Vγ9Vδ2 T cell-based immune interventions. In this review, we will discuss the rationale, preclinical and clinical data in favor of this therapeutic strategy and the future perspectives of its development.

Citing Articles

Vγ9Vδ2 T-cell immunotherapy in blood cancers: ready for prime time?.

Giannotta C, Autino F, Massaia M Front Immunol. 2023; 14:1167443.

PMID: 37143664 PMC: 10153673. DOI: 10.3389/fimmu.2023.1167443.

The immune suppressive tumor microenvironment in multiple myeloma: The contribution of myeloid-derived suppressor cells.

Giannotta C, Autino F, Massaia M Front Immunol. 2023; 13:1102471.

PMID: 36726975 PMC: 9885853. DOI: 10.3389/fimmu.2022.1102471.

T-Cell-Based Cellular Immunotherapy of Multiple Myeloma: Current Developments.

Simmons G, Castaneda Puglianini O Cancers (Basel). 2022; 14(17).

PMID: 36077787 PMC: 9455067. DOI: 10.3390/cancers14174249.

The Diverse Roles of γδ T Cells in Cancer: From Rapid Immunity to Aggressive Lymphoma.

Schonefeldt S, Wais T, Herling M, Mustjoki S, Bekiaris V, Moriggl R Cancers (Basel). 2021; 13(24).

PMID: 34944832 PMC: 8699114. DOI: 10.3390/cancers13246212.

Impact of Immune Parameters and Immune Dysfunctions on the Prognosis of Patients with Chronic Lymphocytic Leukemia.

Vitale C, Boccellato E, Comba L, Jones R, Perutelli F, Griggio V Cancers (Basel). 2021; 13(15).

PMID: 34359757 PMC: 8345723. DOI: 10.3390/cancers13153856.

References

Abe Y, Muto M, Nieda M, Nakagawa Y, Nicol A, Kaneko T . Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma. Exp Hematol. 2009; 37(8):956-68. DOI: 10.1016/j.exphem.2009.04.008. View

Roelofs A, Jauhiainen M, Monkkonen H, Rogers M, Monkkonen J, Thompson K . Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol. 2008; 144(2):245-50. PMC: 2659391. DOI: 10.1111/j.1365-2141.2008.07435.x. View

Scotet E, Martinez L, Grant E, Barbaras R, Jeno P, Guiraud M . Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity. 2005; 22(1):71-80. DOI: 10.1016/j.immuni.2004.11.012. View

Shachaf C, Perez O, Youssef S, Fan A, Elchuri S, Goldstein M . Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. Blood. 2007; 110(7):2674-84. PMC: 1988916. DOI: 10.1182/blood-2006-09-048033. View

Rey J, Veuillen C, Vey N, Bouabdallah R, Olive D . Natural killer and gammadelta T cells in haematological malignancies: enhancing the immune effectors. Trends Mol Med. 2009; 15(6):275-84. DOI: 10.1016/j.molmed.2009.04.005. View

Maniar A, Zhang X, Lin W, Gastman B, Pauza C, Strome S . Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement. Blood. 2010; 116(10):1726-33. PMC: 3324253. DOI: 10.1182/blood-2009-07-234211. View

Thedrez A, Sabourin C, Gertner J, Devilder M, Allain-Maillet S, Fournie J . Self/non-self discrimination by human gammadelta T cells: simple solutions for a complex issue?. Immunol Rev. 2007; 215:123-35. DOI: 10.1111/j.1600-065X.2006.00468.x. View

Carbone E, Neri P, Mesuraca M, Fulciniti M, Otsuki T, Pende D . HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood. 2004; 105(1):251-8. DOI: 10.1182/blood-2004-04-1422. View

Foster A, Okur F, Biagi E, Lu A, Dotti G, Yvon E . Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine. Leukemia. 2010; 24(3):563-72. PMC: 2836398. DOI: 10.1038/leu.2009.281. View

10.

Kunzmann V, Wilhelm M . Anti-lymphoma effect of gammadelta T cells. Leuk Lymphoma. 2005; 46(5):671-80. DOI: 10.1080/10428190500051893. View

11.

Fiore F, Castella B, Nuschak B, Bertieri R, Mariani S, Bruno B . Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid. Blood. 2007; 110(3):921-7. DOI: 10.1182/blood-2006-09-044321. View

12.

Dieli F, Troye-Blomberg M, Ivanyi J, Fournie J, Krensky A, Bonneville M . Granulysin-dependent killing of intracellular and extracellular Mycobacterium tuberculosis by Vgamma9/Vdelta2 T lymphocytes. J Infect Dis. 2001; 184(8):1082-5. DOI: 10.1086/323600. View

13.

Sturm E, Braakman E, Fisch P, Vreugdenhil R, Sondel P, Bolhuis R . Human V gamma 9-V delta 2 T cell receptor-gamma delta lymphocytes show specificity to Daudi Burkitt's lymphoma cells. J Immunol. 1990; 145(10):3202-8. View

14.

Uchida R, Ashihara E, Sato K, Kimura S, Kuroda J, Takeuchi M . Gamma delta T cells kill myeloma cells by sensing mevalonate metabolites and ICAM-1 molecules on cell surface. Biochem Biophys Res Commun. 2007; 354(2):613-8. DOI: 10.1016/j.bbrc.2007.01.031. View

15.

Roelofs A, Thompson K, Gordon S, Rogers M . Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res. 2006; 12(20 Pt 2):6222s-6230s. DOI: 10.1158/1078-0432.CCR-06-0843. View

16.

Thompson K, Rogers M . Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro. J Bone Miner Res. 2004; 19(2):278-88. DOI: 10.1359/JBMR.0301230. View

17.

Bennouna J, Bompas E, Neidhardt E, Rolland F, Philip I, Galea C . Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother. 2008; 57(11):1599-609. PMC: 11030608. DOI: 10.1007/s00262-008-0491-8. View

18.

Landgren O, Kyle R . Multiple myeloma, chronic lymphocytic leukaemia and associated precursor diseases. Br J Haematol. 2007; 139(5):717-23. DOI: 10.1111/j.1365-2141.2007.06866.x. View

19.

Gober H, Kistowska M, Angman L, Jeno P, Mori L, De Libero G . Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med. 2003; 197(2):163-8. PMC: 2193814. DOI: 10.1084/jem.20021500. View

20.

Kiladjian J, Visentin G, Viey E, Chevret S, Eclache V, Stirnemann J . Activation of cytotoxic T-cell receptor gammadelta T lymphocytes in response to specific stimulation in myelodysplastic syndromes. Haematologica. 2008; 93(3):381-9. DOI: 10.3324/haematol.11812. View